Dr Sarah Walsh's Outputs (2)

Pharmacology of non-psychoactive phytocannabinoids and their potential for treatment of cardiometabolic disease. (2025)
Book Chapter
WAINWRIGHT, C.L. and WALSH, S.K. 2025. Pharmacology of non-psychoactive phytocannabinoids and their potential for treatment of cardiometabolic disease. In Wainwright, C. and Schini-Kerth, V. (eds.) Natural products as sources of novel drugs. Handbook of experimental pharmacology, 287. Cham: Springer [online], pages 61-93. Available from: https://doi.org/10.1007/164_2024_731

The use of Cannabis sativa by humans dates back to the third millennium BC, and it has been utilized in many forms for multiple purposes, including production of fibre and rope, as food and medicine, and (perhaps most notably) for its psychoactive pr... Read More about Pharmacology of non-psychoactive phytocannabinoids and their potential for treatment of cardiometabolic disease..

Short-term oral administration of the Porcupine inhibitor, Wnt-c59, improves the structural and functional features of experimental HFpEF. (2025)
Journal Article
WALSH, S.K. [2025]. Short-term oral administration of the Porcupine inhibitor, Wnt-c59, improves the structural and functional features of experimental HFpEF. Pharmacology research and perspectives [online], (accepted).

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% of heart failure cases globally, and this incidence is increasing due to extended lifespans and accumulating comorbidities. Emerging evidence suggests that Wnt sign... Read More about Short-term oral administration of the Porcupine inhibitor, Wnt-c59, improves the structural and functional features of experimental HFpEF..